Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab for Premenopausal Idiopathic Osteoporosis
NCT04800367Phase 2Active, not recruiting
- Sponsor
- Columbia University
- Start
- Mar 2021
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of romosozumab in idiopathic osteoporosis (IO), sponsored by Columbia University. Started Mar 2021; status: active, not recruiting.
02
Drugs
romosozumab
03
Conditions
idiopathic osteoporosis (IO)
Beyond the preview
Go deeper on NCT04800367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04800367.